

Biopharmaceuticals Market By Type (Monoclonal Antibody, Interferon, Insulin, Growth & Coagulation Factor, Erythropoietin, Vaccine, Hormone, and, Others) and Application (Oncology, Blood Disorder, Metabolic Disease, Infectious Disease, Cardiovascular Disease, Neurological Disease, Immunology, and Others) - Global Opportunity Analysis And Industry Forecast, 2018-2025

https://marketpublishers.com/r/BC945442636EN.html

Date: July 2018 Pages: 255 Price: US\$ 5,370.00 (Single User License) ID: BC945442636EN

Abstracts

Biopharmaceuticals are drugs having a biological origin. These large and complex drugs, which often comprise heterogeneous mixtures, are produced using biotechnology and usually from genetically engineered cells. The global biopharmaceuticals market accounted for \$186,470 million in 2017, and is projected to reach \$526,008 million by 2025, registering a CAGR of 13.8% from 2018 to 2025. The global biopharmaceuticals market is driven by various factors, such as surge in prevalence of chronic diseases and rapid increase in the elderly population globally. Similarly, increase in strategic collaboration among the biopharmaceuticals companies is also expected to boost the market. However, high costs of drug development and a stringent regulatory scenario with respect to biopharmaceuticals are anticipated to impede the market growth. Conversely, increase in purchasing power of emerging economics is anticipated to provide lucrative opportunities to the market players throughout the forecast period.

The global biopharmaceuticals market is segmented based on type, application, and region. Based on type, the market is divided into monoclonal antibody, interferon, insulin, growth and coagulation factor, erythropoietin, vaccine, hormone, and others. By application, it is categorized into oncology, blood disorder, metabolic disease, infectious



disease, cardiovascular disease, neurological disease, immunology, and others. Region-wise, it is analyzed across North America, Europe, Asia-Pacific, and Latin America Middle East and Africa (LAMEA). KEY MARKET BENEFITS

The study provides an in-depth analysis of the global biopharmaceuticals market along with the current trends and future estimations to elucidate the imminent investment pockets.

The report presents a quantitative analysis of the market from 2017 to 2025 to enable stakeholders to capitalize on the prevailing market opportunities.

An extensive analysis of the market based on application assists in understanding the trends in the industry.

The key market players along with their strategies are thoroughly analyzed to understand the competitive outlook of the industry.

KEY MARKET SEGMENTS

By product

Monoclonal antibody

Interferon

Insulin

Growth and coagulation factor

Erythropoietin

Vaccine

Hormone

Others



By application

Oncology

Blood disorder

Metabolic disease

Infectious disease

Cardiovascular disease

Neurological disease

Immunology

Others

By geography

North America

U.S.

Canada

Mexico

Europe

Germany

France

UK

Italy



Spain

Rest of Europe

Asia-Pacific

Japan

China

Australia

India

South Korea

Rest of Asia-Pacific

LAMEA

Brazil

Saudi Arabia

South Africa

Rest of LAMEA

The list of key players operating in this market includes:

Abbott Laboratories

Amgen, Inc.

Biogen, Inc.

Eli Lilly and Company



F. Hoffmann-La Roche, Ltd.

Johnson & Johnson

Merck & Co., Inc.

Novo Nordisk A/S

Pfizer, Inc.

Sanofi

The other players included in the value chain analysis (and not included in the report) include:

Bristol Myers Squibb Company

Bayer AG

Shire plc



Contents

CHAPTER 1: INTRODUCTION

- 1.1. Report description
- 1.2. Key benefits for stakeholders
- 1.3. Key market segments
- 1.3.1. List of key players profiled in the report
- 1.4. Research methodology
- 1.4.1. Secondary research
- 1.4.2. Primary research
- 1.4.3. Analyst tools and models

CHAPTER 2: EXECUTIVE SUMMARY

- 2.1. Key findings of the study
 - 2.1.1. CXO perspective

CHAPTER 3: MARKET OVERVIEW

- 3.1. Market definition and scope
- 3.2. Key findings
 - 3.2.1. Top investment pockets
- 3.2.2. Top winning strategies
- 3.3. Market Share Analysis, 2017
- 3.4. Clinical trials
- 3.5. Patent analysis, 2014-2018
 - 3.5.1. Patent analysis, by year (2014-2018)
 - 3.5.2. Patent analysis, by country
- 3.6. Market dynamics
 - 3.6.1. Drivers
 - 3.6.1.1. Increase in prevalence of chronic diseases
 - 3.6.1.2. Rise in geriatric population and improvement in healthcare infrastructure
 - 3.6.1.3. Increase in strategic acquisitions and collaborations
 - 3.6.2. Restraints
 - 3.6.2.1. High cost of drug development and threat of failure
 - 3.6.2.2. Stringent regulatory scenario
 - 3.6.3. Opportunity
 - 3.6.3.1. Increase in purchasing power of emerging economics



CHAPTER 4: BIOPHARMACEUTICALS MARKET, BY TYPE

4.1. Overview

- 4.1.1. Market size and forecast
- 4.2. Monoclonal Antibodies
 - 4.2.1. Key market trends, growth factors and opportunities
 - 4.2.2. Market size and forecast, by region
 - 4.2.3. Market analysis, by country
- 4.3. Interferons
- 4.3.1. Key market trends, growth factors and opportunities
- 4.3.2. Market size and forecast, by region
- 4.3.3. Market analysis, by country
- 4.4. Insulin
 - 4.4.1. Key market trends, growth factors and opportunities
 - 4.4.2. Market size and forecast, by region
- 4.4.3. Market analysis, by country
- 4.5. Growth and coagulation factors
 - 4.5.1. Key market trends, growth factors and opportunities
 - 4.5.2. Market size and forecast, by region
 - 4.5.3. Market analysis, by country
- 4.6. Erythropoietin
- 4.6.1. Key market trends, growth factors and opportunities
- 4.6.2. Market size and forecast, by region
- 4.6.3. Market analysis, by country
- 4.7. Vaccines
 - 4.7.1. Key market trends, growth factors and opportunities
 - 4.7.2. Market size and forecast, by region
- 4.7.3. Market analysis, by country
- 4.8. Hormones
- 4.8.1. Key market trends, growth factors and opportunities
- 4.8.2. Market size and forecast, by region
- 4.8.3. Market analysis, by country
- 4.9. Other
 - 4.9.1. Key market trends, growth factors and opportunities
 - 4.9.2. Market size and forecast, by region
 - 4.9.3. Market analysis, by country

CHAPTER 5: BIOPHARMACEUTICALS MARKET, BY APPLICATION



- 5.1. Overview
 - 5.1.1. Market size and forecast
- 5.2. Oncology
- 5.2.1. Market size and forecast, by region
- 5.2.2. Market analysis, by country
- 5.3. Blood Disorders
- 5.3.1. Market size and forecast, by region
- 5.3.2. Market analysis, by country
- 5.4. Metabolic Diseases
- 5.4.1. Market size and forecast, by region
- 5.4.2. Market analysis, by country
- 5.5. Infectious Diseases
- 5.5.1. Market size and forecast, by region
- 5.5.2. Market analysis, by country
- 5.6. Cardiovascular Diseases
 - 5.6.1. Market size and forecast, by region
- 5.6.2. Market analysis, by country
- 5.7. Neurological Diseases
 - 5.7.1. Market size and forecast, by region
- 5.7.2. Market analysis, by country
- 5.8. Immunology
- 5.8.1. Market size and forecast, by region
- 5.8.2. Market analysis, by country
- 5.9. Other Applications
- 5.9.1. Market size and forecast, by region
- 5.9.2. Market analysis, by country

CHAPTER 6: BIOPHARMACEUTICALS MARKET, BY REGION

- 6.1. Overview
- 6.1.1. Market size and forecast
- 6.2. North America
 - 6.2.1. Key market trends, growth factors, and opportunities
 - 6.2.2. North America Biopharmaceuticals market size and forecast, by country
 - 6.2.2.1. U.S. market size and forecast
 - 6.2.2.1.1. U.S. Biopharmaceuticals market, by type
 - 6.2.2.1.2. U.S. Biopharmaceuticals market, by application
 - 6.2.2.2. Canada market size and forecast



- 6.2.2.2.1. Canada Biopharmaceuticals market, by type
- 6.2.2.2.2. Canada Biopharmaceuticals market, by application
- 6.2.2.3. Mexico market size and forecast
 - 6.2.2.3.1. Mexico Biopharmaceuticals market, by type
- 6.2.2.3.2. Mexico Biopharmaceuticals market, by application
- 6.2.3. North America Biopharmaceuticals market size and forecast, by type
- 6.2.4. North America Biopharmaceuticals market size and forecast, by application
- 6.3. Europe
 - 6.3.1. Key market trends, growth factors and opportunities
 - 6.3.2. Europe Biopharmaceuticals market size and forecast, by country
 - 6.3.2.1. Germany market size and forecast
 - 6.3.2.1.1. Germany. Biopharmaceuticals market, by type
 - 6.3.2.1.2. Germany Biopharmaceuticals market, by application
 - 6.3.2.2. France market size and forecast
 - 6.3.2.2.1. France Biopharmaceuticals market, by type
 - 6.3.2.2.2. France Biopharmaceuticals market, by application
 - 6.3.2.3. UK market size and forecast
 - 6.3.2.3.1. UK Biopharmaceuticals market, by type
 - 6.3.2.3.2. UK Biopharmaceuticals market, by application
 - 6.3.2.4. Italy market size and forecast
 - 6.3.2.4.1. Italy Biopharmaceuticals market, by type
 - 6.3.2.4.2. Italy Biopharmaceuticals market, by application
 - 6.3.2.5. Spain market size and forecast
 - 6.3.2.5.1. Spain. Biopharmaceuticals market, by type
 - 6.3.2.5.2. Spain Biopharmaceuticals market, by application
 - 6.3.2.6. Rest of Europe market size and forecast
 - 6.3.2.6.1. Rest of Europe Biopharmaceuticals market, by type
 - 6.3.2.6.2. Rest of Europe Biopharmaceuticals market, by application
 - 6.3.3. Europe Biopharmaceuticals market size and forecast, by type
- 6.3.4. Europe Biopharmaceuticals market size and forecast, by application
- 6.4. Asia-Pacific
 - 6.4.1. Key market trends, growth factors and opportunities
- 6.4.2. Asia-Pacific Biopharmaceuticals market size and forecast, by country
 - 6.4.2.1. Japan market size and forecast
 - 6.4.2.1.1. Japan Biopharmaceuticals market, by type
 - 6.4.2.1.2. Japan Biopharmaceuticals market, by application
 - 6.4.2.2. China market size and forecast
 - 6.4.2.2.1. China Biopharmaceuticals market, by type
 - 6.4.2.2.2. China Biopharmaceuticals market, by application



6.4.2.3. India market size and forecast

- 6.4.2.3.1. India Biopharmaceuticals market, by type
- 6.4.2.3.2. India Biopharmaceuticals market, by application
- 6.4.2.4. Australia market size and forecast
- 6.4.2.4.1. Australia Biopharmaceuticals market, by type
- 6.4.2.4.2. Australia Biopharmaceuticals market, by application
- 6.4.2.5. South Korea market size and forecast
- 6.4.2.5.1. South Korea Biopharmaceuticals market, by type
- 6.4.2.5.2. South Korea Biopharmaceuticals market, by application
- 6.4.2.6. Rest of Asia-Pacific market size and forecast
 - 6.4.2.6.1. Rest of Asia-Pacific Biopharmaceuticals market, by type
- 6.4.2.6.2. Rest of Asia-Pacific Biopharmaceuticals market, by application
- 6.4.3. Asia-Pacific Biopharmaceuticals market size and forecast, by type
- 6.4.4. Asia-Pacific Biopharmaceuticals market size and forecast, by application 6.5. LAMEA
 - 6.5.1. Key market trends, growth factors and opportunities
 - 6.5.2. LAMEA Biopharmaceuticals market size and forecast, by country
 - 6.5.2.1. Brazil market size and forecast
 - 6.5.2.1.1. Brazil Biopharmaceuticals market, by type
 - 6.5.2.1.2. Brazil Biopharmaceuticals market, by application
 - 6.5.2.2. Saudi Arabia market size and forecast
 - 6.5.2.2.1. Saudi Arabia. Biopharmaceuticals market, by type
 - 6.5.2.2.2. Saudi Arabia Biopharmaceuticals market, by application
 - 6.5.2.3. South Africa market size and forecast
 - 6.5.2.3.1. South Africa Biopharmaceuticals market, by type
 - 6.5.2.3.2. South Africa Biopharmaceuticals market, by application
 - 6.5.2.4. Rest of LAMEA market size and forecast
 - 6.5.2.4.1. Rest of LAMEA Biopharmaceuticals market, by type
 - 6.5.2.4.2. Rest of LAMEA Biopharmaceuticals market, by application
 - 6.5.3. LAMEA Biopharmaceuticals market size and forecast, by type
 - 6.5.4. LAMEA Biopharmaceuticals market size and forecast, by application

CHAPTER 7: COMPANY PROFILES

- 7.1. Abbott Laboratories
 - 7.1.1. Company overview
 - 7.1.2. Company snapshot
 - 7.1.3. Operating business segments
 - 7.1.4. Product portfolio



- 7.1.5. Business performance
- 7.2. Amgen Inc.
 - 7.2.1. Company overview
 - 7.2.2. Company snapshot
 - 7.2.3. Operating business segments
 - 7.2.4. Product portfolio
 - 7.2.5. Business performance
 - 7.2.6. Key strategic moves and developments
- 7.3. Biogen Inc.
 - 7.3.1. Company overview
- 7.3.2. Company snapshot
- 7.3.3. Operating business segments
- 7.3.4. Product portfolio
- 7.3.5. Business performance
- 7.3.6. Key strategic moves and developments
- 7.4. Eli Lilly and Company
 - 7.4.1. Company overview
 - 7.4.2. Company snapshot
 - 7.4.3. Operating business segments
 - 7.4.4. Product portfolio
 - 7.4.5. Business performance
- 7.4.6. Key strategic moves and developments
- 7.5. F. Hoffmann-La Roche Ltd.
 - 7.5.1. Company overview
 - 7.5.2. Company snapshot
 - 7.5.3. Operating business segments
 - 7.5.4. Product portfolio
 - 7.5.5. Business performance
 - 7.5.6. Key strategic moves and developments
- 7.6. Johnson & Johnson
 - 7.6.1. Company overview
 - 7.6.2. Company snapshot
 - 7.6.3. Operating business segments
 - 7.6.4. Product portfolio
 - 7.6.5. Business performance
 - 7.6.6. Key strategic moves and developments
- 7.7. Merck & Co., Inc.
 - 7.7.1. Company overview
 - 7.7.2. Company snapshot



- 7.7.3. Operating business segments
- 7.7.4. Product portfolio
- 7.7.5. Business performance
- 7.7.6. Key strategic moves and developments
- 7.8. Novo Nordisk A/S
 - 7.8.1. Company overview
 - 7.8.2. Company snapshot
 - 7.8.3. Operating business segments
 - 7.8.4. Product portfolio
 - 7.8.5. Business performance
 - 7.8.6. Key strategic moves and developments
- 7.9. Pfizer Inc.
 - 7.9.1. Company overview
 - 7.9.2. Company snapshot
 - 7.9.3. Operating business segments
 - 7.9.4. Product portfolio
 - 7.9.5. Business performance
 - 7.9.6. Key strategic moves and developments
- 7.10. Sanofi
 - 7.10.1. Company overview
 - 7.10.2. Company snapshot
 - 7.10.3. Operating business segments
 - 7.10.4. Product portfolio
 - 7.10.5. Business performance
 - 7.10.6. Key strategic moves and developments



List Of Tables

LIST OF TABLES

TABLE 01. COMPLETED CLINICAL TRIALS IN BIOPHARMACEUTICALS MARKET TABLE 02. GLOBAL BIOPHARMACEUTICALS MARKET, BY TYPE, 2017-2025 (\$MILLION) TABLE 03. KEY MONOCLONAL ANTIBODIES TABLE 04. MONOCLONAL ANTIBODIES BIOPHARMACEUTICALS MARKET, BY REGION, 2017-2025 (\$MILLION) TABLE 05. INTERFERONS BIOPHARMACEUTICALS MARKET, BY REGION, 2017-2025 (\$MILLION) TABLE 06. INSULIN BIOPHARMACEUTICALS MARKET, BY REGION, 2017-2025 (\$MILLION) TABLE 07. GROWTH AND COAGULATION FACTORS BIOPHARMACEUTICALS MARKET, BY REGION, 2017-2025 (\$MILLION) TABLE 08. ERYTHROPOIETIN BIOPHARMACEUTICALS MARKET, BY REGION, 2017-2025 (\$MILLION) TABLE 09. VACCINES BIOPHARMACEUTICALS MARKET, BY REGION, 2017-2025 (\$MILLION) TABLE 10. HORMONES BIOPHARMACEUTICALS MARKET, BY REGION, 2017-2025 (\$MILLION) TABLE 11. OTHER BIOPHARMACEUTICALS MARKET, BY REGION, 2017-2025 (\$MILLION) TABLE 12. GLOBAL BIOPHARMACEUTICALS MARKET, BY APPLICATION, 2017-2025 (\$MILLION) TABLE 13. CANCER: KEY BIOPHARMACEUTICALS TABLE 14. ONCOLOGY BIOPHARMACEUTICALS MARKET, BY REGION, 2017-2025 (\$MILLION) TABLE 15. BLOOD DISORDERS: KEY BIOPHARMACEUTICALS TABLE 16. BLOOD DISORDERS BIOPHARMACEUTICALS MARKET, BY REGION, 2017-2025 (\$MILLION) TABLE 17. METABOLIC DISEASES BIOPHARMACEUTICALS MARKET, BY REGION, 2017-2025 (\$MILLION) TABLE 18. INFECTIOUS DISEASES BIOPHARMACEUTICALS MARKET, BY REGION, 2017-2025 (\$MILLION) TABLE 19. CARDIOVASCULAR DISEASES BIOPHARMACEUTICALS MARKET, BY REGION, 2017-2025 (\$MILLION)

TABLE 20. NEUROLOGICAL DISEASES BIOPHARMACEUTICALS MARKET, BY



REGION, 2017-2025 (\$MILLION)

TABLE 21. IMMUNOLOGY BIOPHARMACEUTICALS MARKET, BY REGION,

2017-2025 (\$MILLION)

TABLE 22. OTHER APPLICATIONS BIOPHARMACEUTICALS MARKET, BY REGION,2017-2025 (\$MILLION)

TABLE 23. BIOPHARMACEUTICALS MARKET REVENUE, BY REGION, 2017-2025 (\$MILLION)

TABLE 24. NORTH AMERICA BIOPHARMACEUTICALS MARKET, BY COUNTRY, 2017-2025 (\$MILLION)

TABLE 25. U.S. BIOPHARMACEUTICALS MARKET, BY TYPE, 2017-2025 (\$MILLION)

TABLE 26. U.S. BIOPHARMACEUTICALS MARKET, BY APPLICATION, 2017-2025 (\$MILLION)

TABLE 27. CANADA BIOPHARMACEUTICALS MARKET, BY TYPE, 2017-2025 (\$MILLION)

TABLE 28. CANADA BIOPHARMACEUTICALS MARKET, BY APPLICATION, 2017-2025 (\$MILLION)

TABLE 29. MEXICO BIOPHARMACEUTICALS MARKET, BY TYPE, 2017-2025 (\$MILLION)

TABLE 30. MEXICO BIOPHARMACEUTICALS MARKET, BY APPLICATION,

2017-2025 (\$MILLION)

TABLE 31. NORTH AMERICA BIOPHARMACEUTICALS MARKET, BY TYPE,

2017-2025 (\$MILLION)

TABLE 32. NORTH AMERICA BIOPHARMACEUTICALS MARKET, BY APPLICATION, 2017-2025 (\$MILLION)

TABLE 33. EUROPE BIOPHARMACEUTICALS MARKET, BY COUNTRY, 2017-2025 (\$MILLION)

TABLE 34. GERMANY BIOPHARMACEUTICALS MARKET, BY TYPE, 2017-2025 (\$MILLION)

TABLE 35. GERMANY BIOPHARMACEUTICALS MARKET, BY APPLICATION, 2017-2025 (\$MILLION)

TABLE 36. FRANCE BIOPHARMACEUTICALS MARKET, BY TYPE, 2017-2025 (\$MILLION)

TABLE 37. FRANCE BIOPHARMACEUTICALS MARKET, BY APPLICATION,2017-2025 (\$MILLION)

TABLE 38. UK BIOPHARMACEUTICALS MARKET, BY TYPE, 2017-2025 (\$MILLION) TABLE 39. UK BIOPHARMACEUTICALS MARKET, BY APPLICATION, 2017-2025 (\$MILLION)

TABLE 40. ITALY BIOPHARMACEUTICALS MARKET, BY TYPE, 2017-2025



(\$MILLION)

TABLE 41. ITALY BIOPHARMACEUTICALS MARKET, BY APPLICATION, 2017-2025 (\$MILLION)

TABLE 42. SPAIN BIOPHARMACEUTICALS MARKET, BY TYPE, 2017-2025 (\$MILLION)

TABLE 43. SPAIN BIOPHARMACEUTICALS MARKET, BY APPLICATION, 2017-2025 (\$MILLION)

TABLE 44. REST OF EUROPE BIOPHARMACEUTICALS MARKET, BY TYPE, 2017-2025 (\$MILLION)

TABLE 45. REST OF EUROPE BIOPHARMACEUTICALS MARKET, BY APPLICATION, 2017-2025 (\$MILLION)

TABLE 46. EUROPE BIOPHARMACEUTICALS MARKET, BY TYPE, 2017-2025 (\$MILLION)

TABLE 47. EUROPE BIOPHARMACEUTICALS MARKET, BY APPLICATION,2017-2025 (\$MILLION)

TABLE 48. ASIA-PACIFIC BIOPHARMACEUTICALS MARKET, BY COUNTRY, 2017-2025 (\$MILLION)

TABLE 49. JAPAN BIOPHARMACEUTICALS MARKET, BY TYPE, 2017-2025 (\$MILLION)

TABLE 50. JAPAN BIOPHARMACEUTICALS MARKET, BY APPLICATION, 2017-2025 (\$MILLION)

TABLE 51. CHINA BIOPHARMACEUTICALS MARKET, BY TYPE, 2017-2025 (\$MILLION)

TABLE 52. CHINA BIOPHARMACEUTICALS MARKET, BY APPLICATION, 2017-2025 (\$MILLION)

TABLE 53. INDIA BIOPHARMACEUTICALS MARKET, BY TYPE, 2017-2025 (\$MILLION)

TABLE 54. INDIA BIOPHARMACEUTICALS MARKET, BY APPLICATION, 2017-2025 (\$MILLION)

TABLE 55. AUSTRALIA BIOPHARMACEUTICALS MARKET, BY TYPE, 2017-2025 (\$MILLION)

TABLE 56. AUSTRALIA BIOPHARMACEUTICALS MARKET, BY APPLICATION, 2017-2025 (\$MILLION)

TABLE 57. SOUTH KOREA BIOPHARMACEUTICALS MARKET, BY TYPE, 2017-2025 (\$MILLION)

TABLE 58. SOUTH KOREA BIOPHARMACEUTICALS MARKET, BY APPLICATION, 2017-2025 (\$MILLION)

TABLE 59. REST OF ASIA-PACIFIC BIOPHARMACEUTICALS MARKET, BY TYPE, 2017-2025 (\$MILLION)



TABLE 60. REST OF ASIA-PACIFIC BIOPHARMACEUTICALS MARKET, BY APPLICATION, 2017-2025 (\$MILLION)

TABLE 61. ASIA-PACIFIC BIOPHARMACEUTICALS MARKET, BY TYPE, 2017-2025 (\$MILLION)

TABLE 62. ASIA-PACIFIC BIOPHARMACEUTICALS MARKET, BY APPLICATION, 2017-2025 (\$MILLION)

TABLE 63. LAMEA BIOPHARMACEUTICALS MARKET, BY COUNTRY, 2017-2025 (\$MILLION)

TABLE 64. BRAZIL. BIOPHARMACEUTICALS MARKET, BY TYPE, 2017-2025 (\$MILLION)

TABLE 65. BRAZIL BIOPHARMACEUTICALS MARKET, BY APPLICATION, 2017-2025 (\$MILLION)

TABLE 66. SAUDI ARABIA BIOPHARMACEUTICALS MARKET, BY TYPE, 2017-2025 (\$MILLION)

TABLE 67. SAUDI ARABIA BIOPHARMACEUTICALS MARKET, BY APPLICATION, 2017-2025 (\$MILLION)

TABLE 68. SOUTH AFRICA BIOPHARMACEUTICALS MARKET, BY TYPE,

2017-2025 (\$MILLION)

TABLE 69. SOUTH AFRICA BIOPHARMACEUTICALS MARKET, BY APPLICATION, 2017-2025 (\$MILLION)

TABLE 70. REST OF LAMEA BIOPHARMACEUTICALS MARKET, BY TYPE,

2017-2025 (\$MILLION)

TABLE 71. REST OF LAMEA BIOPHARMACEUTICALS MARKET, BY APPLICATION, 2017-2025 (\$MILLION)

TABLE 72. LAMEA BIOPHARMACEUTICALS MARKET, BY TYPE, 2017-2025 (\$MILLION)

TABLE 73. LAMEA BIOPHARMACEUTICALS MARKET, BY APPLICATION, 2017-2025 (\$MILLION)

TABLE 74. ABBOTT: COMPANY SNAPSHOT

TABLE 75. ABBOTT: OPERATING SEGMENTS

TABLE 76. ABBOTT: PRODUCT PORTFOLIO

TABLE 77. AMGEN: COMPANY SNAPSHOT

TABLE 78. AMGEN: PRODUCT PORTFOLIO

TABLE 79. BIOGEN: COMPANY SNAPSHOT

TABLE 80. BIOGEN: PRODUCT PORTFOLIO

TABLE 81. LILLY: COMPANY SNAPSHOT

TABLE 82. LILLY: OPERATING SEGMENTS

TABLE 83. LILLY: PRODUCT PORTFOLIO

TABLE 84. ROCHE: COMPANY SNAPSHOT



TABLE 85. ROCHE: OPERATING SEGMENTS TABLE 86. ROCHE: PRODUCT PORTFOLIO TABLE 87. J&J: COMPANY SNAPSHOT TABLE 88. J&J: OPERATING SEGMENTS TABLE 89. J&J: PRODUCT PORTFOLIO TABLE 90. MERCK: COMPANY SNAPSHOT **TABLE 91. MERCK: OPERATING SEGMENTS** TABLE 92. MERCK: PRODUCT PORTFOLIO TABLE 93, NOVO NORDISK: COMPANY SNAPSHOT TABLE 94, NOVO NORDISK: OPERATING SEGMENTS TABLE 95, NOVO NORDISK: PRODUCT PORTFOLIO TABLE 96. PFIZER: COMPANY SNAPSHOT TABLE 97. PFIZER: OPERATING SEGMENTS TABLE 98. PFIZER: PRODUCT PORTFOLIO TABLE 99, SANOFI: COMPANY SNAPSHOT TABLE 100. SANOFI: OPERATING SEGMENTS TABLE 101. SANOFI: PRODUCT PORTFOLIO



List Of Figures

LIST OF FIGURES

FIGURE 01. BIOPHARMACEUTICALS MARKET SEGMENTATION FIGURE 02. TOP INVESTMENT POCKETS FIGURE 03. TOP WINNING STRATEGIES, BY YEAR, 2014-2018 FIGURE 04. TOP WINNING STRATEGIES, BY DEVELOPMENT, 2014-2018 (%) FIGURE 05. TOP WINNING STRATEGIES, BY COMPANY, 2014-2018 FIGURE 06. MARKET SHARE ANALYSIS, 2017 FIGURE 07. PATENT REGISTERED/APPROVED, BY YEAR FIGURE 08. PATENT REGISTERED, BY COUNTRY FIGURE 09. BIOPHARMACEUTICALS MARKET: IMPACT ANALYSES FIGURE 10. DIABETES BURDEN: KEY TAKEAWAYS FIGURE 11. GLOBAL ELDERLY POPULATION (AGED 65 AND ABOVE), BY REGION (2015, 2030, AND 2050) FIGURE 12. COMPARATIVE COUNTRY ANALYSIS OF MONOCLONAL ANTIBODIES **BIOPHARMACEUTICALS MARKET, 2017 AND 2025 (\$MILLION)** FIGURE 13. COMPARATIVE COUNTRY ANALYSIS OF INTERFERONS BIOPHARMACEUTICALS MARKET, 2017 AND 2025 (\$MILLION) FIGURE 14. COMPARATIVE COUNTRY ANALYSIS OF INSULIN BIOPHARMACEUTICALS MARKET, 2017 AND 2025 (\$MILLION) FIGURE 15. COMPARATIVE COUNTRY ANALYSIS OF GROWTH AND COAGULATION FACTORS BIOPHARMACEUTICALS MARKET, 2017 AND 2025 (\$MILLION) FIGURE 16. COMPARATIVE COUNTRY ANALYSIS OF ERYTHROPOIETIN **BIOPHARMACEUTICALS MARKET, 2017 AND 2025 (\$MILLION)** FIGURE 17. COMPARATIVE COUNTRY ANALYSIS OF VACCINES **BIOPHARMACEUTICALS MARKET, 2017 AND 2025 (\$MILLION)** FIGURE 18. COMPARATIVE COUNTRY ANALYSIS OF HORMONES **BIOPHARMACEUTICALS MARKET, 2017 AND 2025 (\$MILLION)** FIGURE 19. COMPARATIVE COUNTRY ANALYSIS OF OTHER **BIOPHARMACEUTICALS MARKET, 2017 AND 2025 (\$MILLION)** FIGURE 20. COMPARATIVE COUNTRY ANALYSIS OF ONCOLOGY **BIOPHARMACEUTICALS MARKET, 2017 AND 2025 (\$MILLION)** FIGURE 21. COMPARATIVE COUNTRY ANALYSIS OF BLOOD DISORDERS **BIOPHARMACEUTICALS MARKET, 2017 AND 2025 (\$MILLION)** FIGURE 22. COMPARATIVE COUNTRY ANALYSIS OF METABOLIC DISEASES BIOPHARMACEUTICALS MARKET, 2017 AND 2025 (\$MILLION)



FIGURE 23. HEPATITIS: KEY FACTS FIGURE 24. COMPARATIVE COUNTRY ANALYSIS OF INFECTIOUS DISEASES BIOPHARMACEUTICALS MARKET, 2017 AND 2025 (\$MILLION) FIGURE 25. COMPARATIVE COUNTRY ANALYSIS OF CARDIOVASCULAR DISEASES BIOPHARMACEUTICALS MARKET, 2017 AND 2025 (\$MILLION) FIGURE 26. COMPARATIVE COUNTRY ANALYSIS OF NEUROLOGICAL DISEASES **BIOPHARMACEUTICALS MARKET, 2017 AND 2025 (\$MILLION)** FIGURE 27. COMPARATIVE COUNTRY ANALYSIS OF IMMUNOLOGY BIOPHARMACEUTICALS MARKET, 2017 AND 2025 (\$MILLION) FIGURE 28. COMPARATIVE COUNTRY ANALYSIS OF OTHER APPLICATIONS **BIOPHARMACEUTICALS MARKET, 2017 AND 2025 (\$MILLION)** FIGURE 29. ABBOTT: NET SALES, 2015-2017 (\$MILLION) FIGURE 30. ABBOTT: REVENUE SHARE BY SEGMENT, 2017 (%) FIGURE 31. ABBOTT: REVENUE SHARE BY GEOGRAPHY, 2017 (%) FIGURE 32. AMGEN: NET SALES, 2015-2017 (\$MILLION) FIGURE 33. AMGEN: REVENUE SHARE BY PRODUCT, 2017 (%) FIGURE 34. AMGEN: REVENUE SHARE BY GEOGRAPHY, 2017 (%) FIGURE 35. BIOGEN: REVENUE, 2015-2017 (\$MILLION) FIGURE 36. BIOGEN: REVENUE SHARE BY PRODUCT, 2017 (%) FIGURE 37. BIOGEN: REVENUE SHARE BY GEOGRAPHY, 2017 (%) FIGURE 38. LILLY: NET SALES, 2015-2017 (\$MILLION) FIGURE 39. LILLY: REVENUE SHARE BY SEGMENT, 2017 (%) FIGURE 40. LILLY: REVENUE SHARE BY GEOGRAPHY, 2017 (%) FIGURE 41. ROCHE: NET SALES, 2015-2017 (\$MILLION) FIGURE 42. ROCHE: REVENUE SHARE BY SEGMENT, 2017 (%) FIGURE 43. ROCHE: REVENUE SHARE BY GEOGRAPHY, 2017 (%) FIGURE 44. J&J: NET SALES, 2015-2017 (\$MILLION) FIGURE 45. J&J: REVENUE SHARE BY SEGMENT, 2017 (%) FIGURE 46. J&J: REVENUE SHARE BY GEOGRAPHY, 2017 (%) FIGURE 47. MERCK: NET SALES, 2015-2017 (\$MILLION) FIGURE 48. MERCK: REVENUE SHARE BY SEGMENT, 2017 (%) FIGURE 49. MERCK: REVENUE SHARE BY GEOGRAPHY, 2016 (%) FIGURE 50. NOVO NORDISK: NET SALES, 2015-2017 (\$MILLION) FIGURE 51. NOVO NORDISK: REVENUE SHARE BY SEGMENT, 2017 (%) FIGURE 52. NOVO NORDISK: REVENUE SHARE BY GEOGRAPHY, 2017 (%) FIGURE 53. PFIZER: NET SALES, 2015-2017 (\$MILLION) FIGURE 54. PFIZER: REVENUE SHARE BY SEGMENT, 2017 (%) FIGURE 55. PFIZER: REVENUE SHARE BY GEOGRAPHY, 2017 (%) FIGURE 56. SANOFI: NET SALES, 2015-2017 (\$MILLION)



FIGURE 57. SANOFI: REVENUE SHARE BY SEGMENT, 2017 (%) FIGURE 58. SANOFI: REVENUE SHARE BY GEOGRAPHY, 2017 (%)



I would like to order

Product name: Biopharmaceuticals Market By Type (Monoclonal Antibody, Interferon, Insulin, Growth & Coagulation Factor, Erythropoietin, Vaccine, Hormone, and, Others) and Application (Oncology, Blood Disorder, Metabolic Disease, Infectious Disease, Cardiovascular Disease, Neurological Disease, Immunology, and Others) - Global Opportunity Analysis And Industry Forecast, 2018-2025

Product link: https://marketpublishers.com/r/BC945442636EN.html

Price: US\$ 5,370.00 (Single User License / Electronic Delivery) If you want to order Corporate License or Hard Copy, please, contact our Customer Service: <u>info@marketpublishers.com</u>

Intoemarketpublishers

Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <u>https://marketpublishers.com/r/BC945442636EN.html</u>

To pay by Wire Transfer, please, fill in your contact details in the form below:

First name: Last name: Email: Company: Address: City: Zip code: Country: Tel: Fax: Your message:

**All fields are required

Custumer signature _

Please, note that by ordering from marketpublishers.com you are agreeing to our Terms & Conditions at <u>https://marketpublishers.com/docs/terms.html</u>



To place an order via fax simply print this form, fill in the information below and fax the completed form to +44 20 7900 3970